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Sarcoplasmic reticulumType-2 ryanodine receptors (RyR2) – the calcium release channels of cardiac sarcoplasmic reticulum – have a
central role in cardiac excitation–contraction coupling. In the heart, ischemia/reperfusion causes a rapid and
signiﬁcant decrease in RyR2 content but the mechanisms responsible for this effect are not fully understood.
We have studied the involvement of three proteolytic systems – calpains, the proteasome and autophagy –
on the degradation of RyR2 in rat neonatal cardiomyocyte cultures subjected to simulated ischemia/
reperfusion (sI/R). We found that 8 h of ischemia followed by 16 h of reperfusion decreased RyR2 content by
50% without any changes in RyR2 mRNA. Speciﬁc inhibitors of calpains and the proteasome prevented the
decrease of RyR2 caused by sI/R, implicating both pathways in its degradation. Proteasome inhibitors also
prevented the degradation of calpastatin, the endogenous calpain inhibitor, hindering the activation of
calpain induced by calpastatin degradation. Autophagy was activated during sI/R as evidenced by the
increase in LC3-II and beclin-1, two proteins involved in autophagosome generation, and in the emergence of
GFP-LC3 containing vacuoles in adenovirus GFP-LC3 transduced cardiomyocytes. Selective autophagy
inhibition, however, induced even further RyR2 degradation, making unlikely the participation of autophagy
in sI/R-induced RyR2 degradation. Our results suggest that calpain activation as a result of proteasome-
induced degradation of calpastatin initiates RyR2 proteolysis, which is followed by proteasome-dependent
degradation of the resulting RyR2 fragments. The decrease in RyR2 content during ischemia/reperfusion may
be relevant to the decrease of heart contractility after ischemia.cted at Instituto de Ciencias
Independencia 1027, Santiago
cultad de Ciencias Químicas y
go 8380492, Chile. Fax: +56 2
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Ischemia/reperfusion (I/R) injury is a major cause of cell death in
the heart [1]. The generation of reactive oxygen species and the
increase in intracellular calcium concentration during ischemia and
the subsequent reperfusion produce oxidative modiﬁcation and
proteolysis of several cardiac proteins [2–4], including sarcoplasmic
reticulum (SR) calcium handling proteins such as ryanodine receptors
(RyR2), sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) and
phospholamban [2,3,5–7]. The decrease in the content of these SR
proteins may exacerbate the characteristic calcium mishandling
observed after I/R [8]. RyR2, the calcium release channels of cardiacsarcoplasmic reticulum, are particularly susceptible to ischemic
injury. The tissue content of RyR2 decreases (50 to 70%) after
ischemia [9] or after I/R [3,5]. RyR2 plays a crucial role in cardiac
excitation–contraction coupling and its rapid down regulation during
I/R may adversely affect cardiac cell recovery and functionality [7,10].
Greater understanding of the pathways involved in RyR2 degradation
is therefore relevant for our ability to counteract the deleterious
consequences of ischemia/reperfusion.
Calpains are calcium-dependent cysteine proteases activated
during I/R, and are therefore potential contributors to RyR2
degradation [3]. Calpains, however, produce only limited proteolysis
of their substrates and other proteolytic pathways further degrade the
resulting fragments [11].
There are two other systems involved in cellular protein
degradation in cardiac myocytes—macroautophagy and the ubiqui-
tin–proteasome complex. Macroautophagy, from now on referred to
simply as autophagy, is a degradative process whereby damaged
proteins or organelles are sequestered in double membrane autopha-
gosomes that fuse with lysosomes, where they are fully degraded and
their aminoacids are recycled [12–14]. The proteasome is a barrel-
Fig. 1. Effect of simulated ischemia–reperfusion on cardiomyocyte death. (A) Release of
LDH to the culture medium was determined as an index of necrosis and was expressed
as % of total activity (n=7) (B) DNA fragmentation was detected by measuring sub-G1
DNAwith propidium iodide labelling followed by ﬂow cytometry in permeabilized cells
(n=3). Results are expressed as relative sub-G1 DNA respect to C/R. (C) A
representative Western blot for carbonylated protein content of total cell lysate (left)
and Coomassie Blue staining of the same PVDF membrane as load control (right).
Values are given as mean±SEM. *P<0.05.
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proteins [15,16].
The aim of this work was to investigate the contribution of
calpains, the proteasome and autophagy to RyR2 degradation




Dulbecco's modiﬁed Eagle's medium (DMEM), M199 medium, 2-
deoxy-D-glucose, pancreatin, 3-methyladenine, E64d and clasto-
lactacystin-β-lactone were purchased from Sigma-Aldrich Corp.
Fetal bovine serum (FBS), penicillin and streptomycin were supplied
by Biological Industries. Collagenase and newborn calf serum were
obtained from Invitrogen (Paisley, Scotland, UK). Plastic Petri dishes
were purchased from Falcon (BD Biosciences, Oxford, UK). MG-132
was acquired from Calbiochem and all other chemicals were of
analytical grade and purchased from Merck Ltd. (Poole, Dorset, UK).
2.2. Primary culture
All animal experimentswere approved by the Animal Care and Use
Committee of the University of Chile and conformed to the Guide for
the Care and Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85-23, 1996). Cardiomyo-
cytes were isolated from hearts from one- to three-day-old Sprague
Dawley rats by enzymatic digestion using pancreatin (1.2 mg/ml) and
collagenase (0.2 mg/ml) as described previously [17]. Cells were pre-
plated to discard non-myocyte cells and the myocyte-enriched
fraction was plated at 1.0×106 cells/mm2 on gelatin-precoated 35-
mmdishes and grown in DMEM/M199 (4:1) mediumwith 10% (w/v)
FBS for 24 h before the experiments. Cardiomyocyte cultures were at
least 95% pure as evaluated either morphologically or with anti-β-
myosin heavy chain antibody (Vector Laboratories, Burlingame, CA,
US) as described [18].
2.3. Simulated ischemia/reperfusion
Cells were incubated in ischemia-mimicking solutions containing
(in mM) HEPES (5), 2-deoxy-D-glucose (10), NaCl (139), KCl (12),
MgCl2 (0.5), CaCl2 (1.3), and lactic acid (20), pH 6.2, under 100%
nitrogen (O2<1%) at 37 °C for 8 h. The lack of glucose or other
nutrients together with the low pH and high potassium and lactate
concentrations, mimics the changes occurring in the myocardium in
vivo during no-ﬂow ischemia [19]. Reperfusion was initiated by
changing the ischemia-mimicking solution to DMEM/M199 (4:1)
supplementedwith 10% (w/v) FBS; incubationwas continued for 16 h
in 95% air, 5% CO2. Parallel controls were similarly incubated but in
buffer containing (in mM) HEPES (5), D-glucose (23), NaCl (139), KCl
(4.7), MgCl2 (0.5), CaCl2 (1.3), pH 7.4 in 95% air, 5% CO2 and were
“reperfused” with the same solutions as cells subjected to sI/R.
2.4. Incubation of cardiomyocytes with inhibitors during simulated
ischemia/reperfusion
To evaluate the involvement of calpains, proteasomes and
autophagy on the degradation of RyR2, we performed sI/R in the
presence of speciﬁc inhibitors for each different degradation pathway.
To inhibit calpains we used 29 µM E64d, a concentration that
completely prevented calpain activation during sI/R. Proteasomes
were inhibited by 25 µM clasto-lactacystin-β-lactone (Lac) or 4.2 µM
MG 132. These concentrations effectively blocked proteasomal
activity, as judged by the accumulation of ubiquitinated proteins
detected in Western blots and were similar to those used in otherworks [20,21]. To inhibit macroautophagy we used 10 mM 3-
methyladenine [22].
2.5. Preparation of whole cell lysates and Western blots
Cardiomyocytes, rinsed twice with PBS to eliminate dead cells,
were homogenized in cold lysis buffer containing (in mM) Tris–HCl
(75), NaCl (225), EDTA (1.5), Nonidet P-40 (4.5%, w/v), sodium
vanadate (5), sodium ﬂuoride (40), sodium pyrophosphate (10), N-
ethylmaleimide (10) and a protease inhibitor cocktail (Complete,
Roche Diagnostics, Mannheim, Germany); ﬁnal pH 7.4. The lysate was
centrifuged at 4 °C (10 min at 10,000 ×g) and the supernatant was
collected. Proteins were separated by SDS-PAGE (3.5–8% gradient gels
Fig. 2. RyR2 protein and mRNA content following simulated ischemia–reperfusion.
(A) Representative Western blots obtained in total cell lysates reacted with anti-RyR2
or anti-β-actin. The bar graphs show the ratio of RyR2/β-actin calculated from
densitometric analysis of Western blots like those shown in the ﬁgure (n=9).
(B) Semi-quantitative RT-PCR for RyR2 and β-actin mRNAs (n=3). Values are given as
mean±SEM. *P<0.05
Fig. 3. Activation of calpains during simulated ischemia–reperfusion results in RyR2
degradation. (A) Effect of E64d (29 µM) during sI/R on calpain activity measured in
vitro in whole cell lysates (n=4). (B) Representative Western blots obtained from total
cell lysates with anti-RyR2 and anti-β-actin. The bar graphs show the ratio of RyR2/β-
actin calculated from densitometric analysis of Western blots like those shown in the
ﬁgure. Values are expressed as mean±SEM. *P<0.05 C/R vs I/R, #P<0.05 I/R vs I/R+
E64d.
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(LC3-II), or 8% gels for beclin-1, calpastatin and ubiquitin) and
transferred onto PVDF membranes (Millipore Corp., Bedford, MA).
Membranes were probedwith the following primary antibodies: anti-
RyR2 (Afﬁnity Bioreagents), anti-LC3B for LC3-I and LC3-II (Cell
Signaling), anti-beclin-1 (Santa Cruz Biotechnology), anti-calpastatin
(Santa Cruz Biotechnology) or anti-β-actin (Sigma). After incubation
with the appropriate secondary antibody, antigen–antibody reaction
was detected by ECL (Amersham, Biosciences). Blots were quantiﬁed
by densitometric analysis using the software Quantity One (BioRad,
Hercules, CA); results were normalized with respect to β-actin, a
protein that did not change in this sI/Rmodel. Blots were only visually
comparedwhen testing with anti-ubiquitin antibodies (Cell Signaling,
1: 200,000 dilution).
2.6. Semi-quantitative RT-PCR
We measured the amounts of RyR2 mRNA during sI/R using the
following oligonucleotides: RyR2 (forward, 5′-CTACTCAGGAT-
GAGGTGCGA-3′; reverse, 5′-CTCTCTTCAGATCCAAGCCA-3′) and β-
actin (forward, 5′-TACATGGCTGGGGTCTTGAA-3′; reverse, 5′-TCTA-
CAATGAGCTGCGTGTG-3′). After DNA denaturation (3 min, 94 °C), the
following thermal proﬁle was performed: 30 cycles of 30 s at 94 °C,
30 s at 52 °C and 1 min at 72 °C plus a ﬁnal 10 min elongation step at
72 °C. Expression of mRNA was evaluated from ethidium bromide-
stained agarose gel electrophoresis. Expression levels were calculated
as the ratio of the respective RyR2 and β-actin bands and normalized
to the control.2.7. Immunocytochemistry of LC3-II
Cardiomyocytes were transducedwith adenovirus GFP-tagged LC3
at a multiplicity of infection of 100 for 4 h before sI/R. Autophago-
somes were quantiﬁed in cardiomyocytes via ﬂuorescence imaging of
GFP-LC3 as described [22].
2.8. Other procedures
Lactate dehydrogenase (LDH) activity in the culture medium,
determined by measuring the decrease in NADH spectrophotometri-
cally at 340 nm, was normalized to total LDH activity. DNA
fragmentation was determined in methanol permeabilized cardio-
myocytes labeled with propidium iodide; the sub-G1 population was
quantiﬁed by ﬂow cytometry [23]. Calpain activity and protein
carbonylation were determined with commercial kits according to
the manufacturer's instructions (Calbiochem and Chemicol Interna-
tional, respectively). Protein was determined according to Hartree
[24].
2.9. Statistical analysis
Data are shown as mean±S.E.M. of the number (n) of indepen-
dent experiments. Data were analyzed by Student's t-test or one-way
ANOVA followed by Tukey's test. Differences were considered
signiﬁcant at P<0.05.
359Z. Pedrozo et al. / Biochimica et Biophysica Acta 1802 (2010) 356–3623. Results
3.1. Characterization of the simulated ischemia/reperfusion model
First, we evaluated the effects of simulated ischemia/reperfusion
on the viability of neonatal cardiomyocytes. Our protocol (ischemia
for 8 h, reperfusion for 16 h) resulted in a diminution in viability
characterized by changes in morphology with appearance of rounded
cells (not shown) and increased LDH leakage (Fig. 1A), suggestive of
necrotic cell death. In contrast, apoptosis, as evaluated by ﬂow
cytometry of propidium iodide-stained cells, was not signiﬁcantly
different after sI/R when compared with time-matched controls
(Fig. 1B). These results indicate that sI/R produces necrotic but not
apoptotic cell death. Our sI/R model was also associated with
increased oxidative stress [2,4,25]. Enhanced protein carbonylation,
a marker of severe oxidative damage, was clearly visibly in several
proteins present in cells extracts obtained after sI/R (Fig. 1C).3.2. Decreased RyR2 content after sI/R in cultured cardiomyocytes
The content of RyR2 decreased signiﬁcantly (50%) in cells
subjected to sI/R (Fig. 2A) in agreement with previous reports
[3,5,9]. The amount of RyR2 mRNA, did not change during sI/R
(Fig. 2B), suggesting that the decrease in RyR2 protein content was
caused by protein degradation.Fig. 4. Proteasomal degradation of RyR2 during simulated ischemia–reperfusion. (A) Repr
obtained from controls or following sI/R in the presence and absence of the proteasome inhib
control (right). (B) Representative Western blots obtained in total cell lysates with anti-RyR
Lac (25 µM) and MG-132 (4.2 µM). The bar graph shows the ratio of RyR2/β-actin calcul
calpastatin or anti-β-actin in total cell lysates from cells in which sI/R was performed in the p
actin calculated from densitometric analysis of Western blots like those shown in the ﬁgure.
whole cell lysates (n=4). Values are expressed as mean±SEM (n=7). *P<0.05 C/R vs I/R3.3. Calpains are involved in RyR2 degradation
Calpains, which are activated during ischemia, contribute to the
degradation of several structural proteins in cardiomyocytes
[2,11,26,27]. The protective effect of leupeptin, a cysteine protease
inhibitor, on RyR2 protein levels suggests that calpains degrade RyR2
during I/R [3]. We measured calpain activity and evaluated the effect
of E64d (29 µM), a speciﬁc calpain inhibitor, on RyR2 degradation.
There was a small but signiﬁcant increase in calpain activity in whole
cell lysates prepared from cardiomyocytes subjected to sI/R and this
was prevented by E64d (Fig. 3A). This calpain inhibitor also prevented
RyR2 degradation during sI/R (Fig. 3B), conﬁrming that calpains
contribute to this degradation. Addition of E64d to cardiomyocytes
did not change RyR2 content under control conditions (not shown)
and had no effect on the appearance of polyubiquitinated proteins in
Western blots (not shown), indicating that proteasomal activity was
insensitive to E64d.
3.4. Proteasomes are involved in RyR2 degradation
The proteasome is the primary site for the degradation of
intracellular proteins [16]. Activation of calpain increases proteasomal
protein degradation [28]. We investigated the effects of two
proteasome inhibitors, clasto-lactacystin-β-lactone (Lac) and MG
132, on sI/R-induced RyR2 degradation. Lac inhibits chymotrypsin-
and trypsin-like proteolytic activities while MG 132, a structurallyesentative Western blot, obtained with anti-ubiquitin antibody, of whole cell lysates
itor Lac (25 µM); Coomassie blue staining of the same PVDFmembrane is shown as load
2 or anti-β-actin in controls and after sI/R in the presence of the proteasome inhibitors
ated by densitometric analysis. (C) Representative Western blots obtained with anti-
resence of the proteasome inhibitor Lac. The bar graphs show the ratio of calpastatin/β-
(D) Effect of Lac on calpain activity during sI/R. The activity was assessed in vitro using
; #P<0.05 I/R vs I/R+Lac or I/R+MG-132.
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lytic activities of the proteasome. Lac (at 25 µM) increased markedly
the amounts of ubiquitinated proteins (Fig. 4A); similar results were
observed with MG 132 (at 4.2 µM, not shown), indicating that these
agents effectively inhibited proteasomal activity at the concentrations
used. Both inhibitors completely prevented the decrease in RyR2
content following sI/R (Fig. 4B). Neither inhibitor affected the amount
of RyR2 in control cardiomyocytes (data not shown).
These results suggest that both calpains and the proteasome
mediate RyR2 degradation during sI/R in cultured cardiomyocytes.
The fact that speciﬁc inhibitors for each pathway can independently
and effectively prevent RyR2 degradation suggests a relationship
between both degradation systems.
The degradation of calpastatin, a highly speciﬁc endogenous
inhibitor of calpain [29], is necessary for calpain activation during I/R
[30]. We measured the content of calpastatin following sI/R and
investigated the effect of proteasome inhibition on calpastatin levels.
The amount of calpastatin was greatly diminished (by 50%) after sI/R
and this decrease was totally prevented by Lac (Fig. 4C). Lac also
prevented the increase in calpain activity observed after sI/R (Fig. 4D).Fig. 5. Inhibition of macroautophagy increased RyR2 degradation during simulated ischemia
whole cell lysates obtained from controls or following sI/R. Blots were assayed with anti-LC3B
beclin-1/β-actin (B, n=6) calculated from densitometric analysis of Western blots like thos
control conditions or following sI/R. Bar graphs represent the percentage of cells exhibiting
blot, obtained with anti-RyR2 or anti-β-actin of whole cell lysates obtained from controls or
graphs show the ratios of RyR2/β-actin calculated by densitometric analysis. Values are exWe conclude that proteasomal activity promotes calpain activation by
inducing the breakdown of calpastatin.
3.5. Autophagy is activated by sI/R but is not implicated in RyR2
degradation
Beclin-1 and LC3-II, two proteins involved in the formation of
autophagosomes, are speciﬁc markers for the activation of autophagy
[12–14,31]. As found in other models of I/R [31,32] there was a
signiﬁcant increase in both LC3-II and beclin-1 after sI/R (Fig. 5A–B),
suggesting that autophagy increased under these conditions. We
conﬁrmed this increase by transducing cells with a GFP-LC3 tagged
adenovirus. Activation of autophagy is seen as a punctuate ﬂuorescent
pattern arising from the formation of autophagic vacuoles [22].
Images obtained by immunoﬂuorescence microscopy of GFP-LC3
transfected cardiomyocytes showed that the number of cells with
vacuoles increased after sI/R (Fig. 5C). These results indicate that
autophagy is activated during sI/R. Inhibition of autophagy by 3-
methyladenine (3-MA; 10 mM) did not prevent, however, the RyR2
decrease induced by sI/R but rather stimulated a further decrease–reperfusion. Representative Western blot, obtained with anti-LC3B or anti-β-actin, of
(A) or anti-Beclin-1 (B). The bar graphs show the ratios of LC3-II/β-actin (A, n=7) and
e shown in the ﬁgure. (C) Fluorescent images of GFP-LC3 transduced cardiomyocytes in
more than 5 vacuoles, a sign of macroautophagy (n=3). (D) Representative Western
following sI/R with and without the macroautophagy inhibitor 3-MA (10 mM). The bar
pressed as mean±SEM (n=6). *P<0.05 C/R vs I/R, #P<0.05 I/R vs I/R+3-MA.
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3-MA in control cells not subjected to sI/R. (Fig. 5D). Autophagy thus
seems not to be involved in the degradation of RyR2 induced by sI/R.
4. Discussion
Our present results indicate that RyR2 is degraded during sI/R by
the concerted actions of calpains and the proteasome. Autophagy, in
contrast, has no role in this process. We have also shown that the
proteasome contributed to calpain activation after sI/R by promoting
breakdown of calpastatin.
In our model system we observed increased oxidative stress and
necrotic cell death but saw no evidence of increased apoptosis, in
agreement with other reports showing that total deprivation of
oxidizable substrates causes cardiomyocyte death exclusively by
necrosis due to the rapid loss of ATP [33]. The extent of LDH leakage
during sI/R represented only 35% of the total LDH, suggesting that this
protocol produced rather mild ischemia (65% of the cells surviving).
Nevertheless, surviving cells exhibited a 50% decrease in RyR2
content. The amounts of RyR2 mRNA were unaffected by sI/R and
the amount of RyR2 protein was sustained when sI/R was accompa-
nied by calpain or proteasome inhibitors. We assume therefore that
RyR2 was degraded by both calpains and the proteasome during sI/R.
Our observation of the role of calpain in RyR2 supports previous
results showing that leupeptin prevents the decrease in RyR2 content
in isolated hearts subjected to I/R [3]. Experiments in vitro have
shown, however, that exogenously added calpain II degrades RyR2 in
isolated cardiac SR vesicles with production of two proteolytic
fragments of 150 and 350 KDa. There was no further degradation of
the 150 KDa fragment even when proteolysis was allowed to proceed
for 30 min at a relatively high concentration of calpain [34]. If calpain
displays similar activity in whole cells, there must be other pathways
for degrading the resulting large RyR2 fragments.
Proteasomes are reportedly inhibited by I/R, but this inhibition is
not complete and depends on the extent and duration of ischemia
[4,35,36]. We did not ﬁnd an increase in ubiquitinated proteins after
sI/R in neonatal cardiomyocytes, suggesting that in our model,
proteasomes were either not inhibited or their remaining activity
was enough to degrade the proteolytic fragments produced by
calpain.
Polyubiquitination is a general signal for proteasomal degradation.
Some forms of polyubiquitination and monoubiquitination, however,
have roles in protein localization, protein function and cell signalling
[37,38]; moreover, oxidized proteins can be degraded by the
proteasome without previous ubiquitination [39]. Accordingly, we
did not investigate the ubiquitination of RyR2 during sI/R because, as
stated above, ubiquitination of one speciﬁc protein cannot be taken as
equivalent to proteasomal degradation. The speciﬁc proteasome
inhibitors, Lac and MG 132, completely prevented RyR2 degradation;
this result, together with the observation that proteasomal inhibition
did not lead to large fragments recognized by the antibody to RyR2,
suggested that calpains were also inhibited in the presence of Lac.
The regulation of calpain in vivo is not fully understood. The
calpain/calpastatin ratio may be a better indicator of calpain potential
activity than calpain activity alone. In isolated hearts subjected to I/R,
the calpain/calpastatin ratio increases shortly after I/R; this increase
occurs mainly through increased calpastatin degradation, which is not
prevented by calpain inhibitors [40]. Although breakdown of
calpastatin by the proteasome has been demonstrated in vitro [41],
this is the ﬁrst evidence for a role of the proteasome in calpastatin
degradation, which in turn promotes calpain activation in cell cultures
during sI/R.
Autophagy, which in the heart, is normally responsible for limited
degradation of long-lived proteins and organelles, is increased
following I/R [31,32]. Changes in speciﬁc marker proteins indicate
that autophagywas also increased in ourmodel of sI/R. RyR2 is a long-lived protein [42]; this feature plus its location in the SR, suggested
that autophagy might be the primary degradation mechanism. Our
results have not supported this hypothesis. The enhanced degradation
of RyR2 produced as a consequence of the inhibition of autophagy
may be attributable to a compensatory up-regulation of proteasomal
activities or other proteolytic pathways.
Neonatal cardiomyocytes are phenotypically different from their
adult counterparts but posses functional RyR2 [43,44]. On the
assumption that proteolytic processing is similar in adult and
neonatal cells, we feel that our model is appropriate for investigation
of RyR2 degradation after sI/R.
In summary our results suggests that proteasomal degradation of
calpastatin during sI/R enhances calpain activation, which in turn
proteolyses RyR2. The resulting fragments are then fully degraded by
the proteasome.
RyR2 has a key role in cardiac excitation–contraction coupling
[45]. Down regulation of RyR2 may be responsible, at least in part, for
the reversible contractile dysfunction, or stunning, that follows IR
[46,47]. RyR2 down regulation will also alter the relative contribution
of SR calcium release and L-type calcium channel-mediated calcium
entry to calcium increase during systole [48]. This change may alter
calcium signalling in the heart and contribute to the adverse cardiac
remodelling produced by myocardial ischemia [49]. The attenuation
of RyR2 degradation by calpain or proteasome inhibitors may serve to
maintain contractile function. This effect could be the basis of the
protective effects of calpastatin overexpression [50] and of inhibitors
of the proteasome [51] or calpain [30] observed in experimental
models of I/R.
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